Clinical Trials Logo

Filter by:
NCT ID: NCT02718716 Completed - Thrombocytopenia Clinical Trials

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Start date: March 2, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

NCT ID: NCT02717546 Completed - Clinical trials for Distal Tibia Fractures

Zimmer® MotionLoc® in Distal Tibia Fractures

Start date: February 2016
Phase:
Study type: Observational

The objective of this observational prospective study is to systematically document the clinical outcomes of Zimmer MotionLoc Screws for Periarticular Locking Plate System applied to distal tibia fracture treatment and confirm safety and performance of the screws.

NCT ID: NCT02716909 Completed - Preterm Birth Clinical Trials

Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth

Start date: March 2016
Phase: Phase 3
Study type: Interventional

Spontaneous preterm birth (SPTB) remains the number one cause of perinatal mortality in many countries, including the United States. In singleton gestations a short cervical length (CL) on transvaginal ultrasound (TVU) has been shown to be a good predictor of SPTB. The cervical pessary is a silicone device that has been used to prevent SPTB. The efficacy of cervical pessary has been assessed in several populations including singletons with short CL, unselected twins, twins with a short CL, and triplet pregnancies. Several randomized clinical trials (RCTs) have been published, and several are ongoing. However, no consensus on the use of cervical pessary in pregnancy or guidelines for management have been assessed.

NCT ID: NCT02716194 Completed - Hemophilia A Clinical Trials

BAX 826 Dose-Escalation Safety Study

Start date: March 3, 2016
Phase: Phase 1
Study type: Interventional

1. To assess tolerability and safety of BAX 826 after a single infusion in previously treated patients (PTPs) with severe hemophilia A 2. To determine the pharmacokinetic (PK) parameters of BAX 826 compared to ADVATE 3. To evaluate immunogenicity of polysialic acid linked to Factor VIII (FVIII)

NCT ID: NCT02714595 Completed - Sepsis Clinical Trials

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

CREDIBLE - CR
Start date: September 7, 2016
Phase: Phase 3
Study type: Interventional

This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

NCT ID: NCT02714517 Completed - Clinical trials for Peripheral Neuropathy

Efficacy of Hydrotherapy in Peripheral Neuropathy

Start date: July 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy of hydrotherapy on pain and balance in patients affected by neuropathy.

NCT ID: NCT02714465 Completed - Cerebral Necrosis Clinical Trials

Adverse Radiation Effects After Gamma Knife Radio Surgery and Hyperbaric Oxygen Therapy

GKSHBO
Start date: March 1, 2016
Phase: N/A
Study type: Interventional

Evaluation of clinical improvement and the reduction of edema lesion documented by magnetic resonance imaging (MRI) in patients with cerebral radiation necrosis post gamma knife surgery (GKS) by treatment with hyperbaric oxygen therapy (HBO)

NCT ID: NCT02714218 Completed - Melanoma Clinical Trials

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Start date: April 4, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

NCT ID: NCT02713867 Completed - Lung Cancer Clinical Trials

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

CheckMate 384
Start date: May 24, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare PFS (progression-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks with nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).

NCT ID: NCT02712983 Completed - Clinical trials for Non-cystic Fibrosis Bronchiectasis

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

iBEST-1
Start date: February 8, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.